BridgeBio Pharma (BBIO) Expected to Release Quarterly Earnings on Tuesday

BridgeBio Pharma (NASDAQ:BBIO) will likely be posting its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect BridgeBio Pharma to post earnings of ($0.63) per share and revenue of $221.1540 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. The firm’s revenue for the quarter was up 66.8% on a year-over-year basis. During the same period last year, the business earned ($0.88) EPS. On average, analysts expect BridgeBio Pharma to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO opened at $84.12 on Tuesday. BridgeBio Pharma has a 12 month low of $42.09 and a 12 month high of $93.42. The firm has a market capitalization of $16.48 billion, a price-to-earnings ratio of -22.49 and a beta of 0.95. The business’s 50 day simple moving average is $73.07 and its 200-day simple moving average is $72.59.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Andrea Ellis sold 17,167 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $84.00, for a total value of $1,442,028.00. Following the transaction, the director directly owned 22,579 shares of the company’s stock, valued at $1,896,636. This trade represents a 43.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $67.46, for a total value of $2,698,400.00. Following the transaction, the chief executive officer owned 535,686 shares in the company, valued at approximately $36,137,377.56. This represents a 6.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 432,117 shares of company stock valued at $32,633,740 over the last ninety days. Insiders own 14.23% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Several large investors have recently bought and sold shares of the company. Global Retirement Partners LLC lifted its position in shares of BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after purchasing an additional 372 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in BridgeBio Pharma in the 4th quarter worth $41,000. Harvest Fund Management Co. Ltd purchased a new position in BridgeBio Pharma in the 3rd quarter valued at about $34,000. Smartleaf Asset Management LLC increased its position in shares of BridgeBio Pharma by 63.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 739 shares of the company’s stock worth $56,000 after acquiring an additional 286 shares during the last quarter. Finally, Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma in the first quarter worth about $35,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BBIO. Raymond James Financial downgraded BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. HC Wainwright raised their price objective on BridgeBio Pharma from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Citigroup upped their price objective on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the company a “neutral” rating in a research note on Thursday, July 16th. Weiss Ratings restated a “sell (d)” rating on shares of BridgeBio Pharma in a report on Friday, May 15th. Finally, Royal Bank Of Canada initiated coverage on shares of BridgeBio Pharma in a report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 target price for the company. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average target price of $95.21.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.